Incyte
Incyte Corporation, a leading biopharmaceutical company headquartered in the United States, has been at the forefront of innovative cancer therapies since its founding in 1991. With a strong focus on oncology, Incyte develops and commercialises novel treatments that address unmet medical needs, particularly in the fields of haematology and solid tumours. The company is renowned for its flagship product, Jakafi (ruxolitinib), which was the first FDA-approved JAK1/JAK2 inhibitor, offering unique therapeutic options for patients with myelofibrosis and polycythaemia vera. Incyte's commitment to research and development has positioned it as a key player in the biopharmaceutical industry, with a robust pipeline of investigational therapies aimed at improving patient outcomes. With a global presence, Incyte continues to make significant strides in advancing cancer care and enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Incyte's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Incyte's score of 30 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Incyte's reported carbon emissions
Incyte, headquartered in the US, reported its carbon emissions for 2023, totalling approximately 10,216,000 kg CO2e for Scope 1 and 2 emissions combined, with Scope 1 emissions at about 9,351,000 kg CO2e and Scope 2 emissions at approximately 865,000 kg CO2e (market-based). Additionally, Scope 3 emissions were reported at approximately 4,549,000 kg CO2e for business travel, 360,000 kg CO2e for waste generated in operations, and 3,830,000 kg CO2e for fuel and energy-related activities. In 2022, Incyte's total emissions for Scope 1 and 2 were about 9,309,000 kg CO2e, with Scope 1 at approximately 8,062,000 kg CO2e and Scope 2 at around 1,247,000 kg CO2e (market-based). Scope 3 emissions for that year were approximately 3,243,000 kg CO2e for business travel, 405,000 kg CO2e for waste, and 3,569,000 kg CO2e for fuel and energy-related activities. Despite these figures, Incyte has not disclosed specific reduction targets or initiatives aimed at decreasing its carbon footprint. The company has not committed to any science-based targets or climate pledges, indicating a potential area for future improvement in its sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 4,775,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 7,451,000 | 0,000,000 | 000,000 | 0,000,000 | 000,000 |
| Scope 3 | 7,165,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Incyte is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
